Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose

Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data

(2011) Rianne M.F. van Schie et al.   EUROPEAN HEART JOURNAL

Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing

(2010) P Lenzini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters

(2010) Christof Geisen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes

(2010) Martina Teichert et al.   Pharmacogenetics and Genomics

New Insights into the Regulation of CYP2C9 Gene Expression: The Role of the Transcription Factor GATA-4

(2009) J. Mwinyi et al.   DRUG METABOLISM AND DISPOSITION

A genome-wide association study of acenocoumarol maintenance dosage

(2009) Martina Teichert et al.   HUMAN MOLECULAR GENETICS

Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose

(2009) Fumihiko Takeuchi et al.   PLoS Genetics

Perifollicular Xanthomatosis as the Hallmark of Axillary Fox-Fordyce Disease

(2008) Adolfo B. Bormate et al.   ARCHIVES OF DERMATOLOGY

Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake Inhibitors and Coumarins

(2008) Tom Schalekamp   ARCHIVES OF INTERNAL MEDICINE

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin

(2008) BF Gage et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice

(2008) Laurent Becquemont   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

VKORC1andCYP2C9allelic variants influence acenocoumarol dose requirements in Greek patients

(2008) Christos N Markatos et al.   PHARMACOGENOMICS